Four questions to predict cognitive decline in de novo Parkinson’s disease
Abstract Early identification of cognitive decline (CD) in de novo Parkinson’s disease (PD) is crucial for choosing appropriate therapies and recruiting for clinical trials. However, existing prognostic models lack flexibility, scalability and require costly instrumentation. This study explores the...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-025-00958-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849712820556398592 |
|---|---|
| author | Jan Hlavnička Josef Mana Ondrej Bezdicek Martin Čihák Filip Havlík Dominik Škrabal Tereza Bartošová Karel Šonka Evžen Růžička Petr Dušek |
| author_facet | Jan Hlavnička Josef Mana Ondrej Bezdicek Martin Čihák Filip Havlík Dominik Škrabal Tereza Bartošová Karel Šonka Evžen Růžička Petr Dušek |
| author_sort | Jan Hlavnička |
| collection | DOAJ |
| description | Abstract Early identification of cognitive decline (CD) in de novo Parkinson’s disease (PD) is crucial for choosing appropriate therapies and recruiting for clinical trials. However, existing prognostic models lack flexibility, scalability and require costly instrumentation. This study explores the utility of standard clinical questionnaires and criteria to predict CD in de novo PD. A total of 186 patients from the Parkinson Progression Markers Initiative (PPMI) and 48 patients from the Biomarkers of Parkinson’s Disease project (BIO-PD) underwent clinical interviews, comprehensive tests, and questionnaires. A model based only on age of disease onset, history of stroke, history of fainting, and vocalization during dreams predicted CD in 2 and 4-year horizons with an area under curve (AUC) of 70% ± 10% standard deviation (cross-validated PPMI), 79% (overall PPMI), and 78% (validation in BIO-PD). This approach enables rapid preliminary screening using just four simple questions, achieving predictive accuracy comparable to instrumentation-based methods while reducing assessment time. |
| format | Article |
| id | doaj-art-583802c14c644d649614cdb0fabfd8bd |
| institution | DOAJ |
| issn | 2373-8057 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Parkinson's Disease |
| spelling | doaj-art-583802c14c644d649614cdb0fabfd8bd2025-08-20T03:14:09ZengNature Portfolionpj Parkinson's Disease2373-80572025-04-0111111010.1038/s41531-025-00958-5Four questions to predict cognitive decline in de novo Parkinson’s diseaseJan Hlavnička0Josef Mana1Ondrej Bezdicek2Martin Čihák3Filip Havlík4Dominik Škrabal5Tereza Bartošová6Karel Šonka7Evžen Růžička8Petr Dušek9Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University HospitalAbstract Early identification of cognitive decline (CD) in de novo Parkinson’s disease (PD) is crucial for choosing appropriate therapies and recruiting for clinical trials. However, existing prognostic models lack flexibility, scalability and require costly instrumentation. This study explores the utility of standard clinical questionnaires and criteria to predict CD in de novo PD. A total of 186 patients from the Parkinson Progression Markers Initiative (PPMI) and 48 patients from the Biomarkers of Parkinson’s Disease project (BIO-PD) underwent clinical interviews, comprehensive tests, and questionnaires. A model based only on age of disease onset, history of stroke, history of fainting, and vocalization during dreams predicted CD in 2 and 4-year horizons with an area under curve (AUC) of 70% ± 10% standard deviation (cross-validated PPMI), 79% (overall PPMI), and 78% (validation in BIO-PD). This approach enables rapid preliminary screening using just four simple questions, achieving predictive accuracy comparable to instrumentation-based methods while reducing assessment time.https://doi.org/10.1038/s41531-025-00958-5 |
| spellingShingle | Jan Hlavnička Josef Mana Ondrej Bezdicek Martin Čihák Filip Havlík Dominik Škrabal Tereza Bartošová Karel Šonka Evžen Růžička Petr Dušek Four questions to predict cognitive decline in de novo Parkinson’s disease npj Parkinson's Disease |
| title | Four questions to predict cognitive decline in de novo Parkinson’s disease |
| title_full | Four questions to predict cognitive decline in de novo Parkinson’s disease |
| title_fullStr | Four questions to predict cognitive decline in de novo Parkinson’s disease |
| title_full_unstemmed | Four questions to predict cognitive decline in de novo Parkinson’s disease |
| title_short | Four questions to predict cognitive decline in de novo Parkinson’s disease |
| title_sort | four questions to predict cognitive decline in de novo parkinson s disease |
| url | https://doi.org/10.1038/s41531-025-00958-5 |
| work_keys_str_mv | AT janhlavnicka fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease AT josefmana fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease AT ondrejbezdicek fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease AT martincihak fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease AT filiphavlik fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease AT dominikskrabal fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease AT terezabartosova fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease AT karelsonka fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease AT evzenruzicka fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease AT petrdusek fourquestionstopredictcognitivedeclineindenovoparkinsonsdisease |